Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prophase Labs Inc (PRPH)

Prophase Labs Inc (PRPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,840
  • Shares Outstanding, K 4,618
  • Annual Sales, $ 6,770 K
  • Annual Income, $ -53,360 K
  • EBIT $ -27 M
  • EBITDA $ -19 M
  • 60-Month Beta -0.66
  • Price/Sales 0.47
  • Price/Cash Flow N/A
  • Price/Book 0.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings $-0.16 on 11/19/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 747.88% (+0.14%)
  • Historical Volatility 171.58%
  • IV Percentile 96%
  • IV Rank 60.59%
  • IV High 1,158.78% on 02/11/25
  • IV Low 116.28% on 10/03/25
  • Expected Move (DTE 21) 0.3315 (63.97%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,181
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 14,914
  • Open Int (30-Day) 14,573
  • Expected Range 0.1867 to 0.8497

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5075 +4.00%
on 12/26/25
2.2000 -76.01%
on 12/01/25
-1.2822 (-70.84%)
since 11/26/25
3-Month
0.5075 +4.00%
on 12/26/25
6.6590 -92.07%
on 10/07/25
-3.8992 (-88.08%)
since 09/26/25
52-Week
0.5075 +4.00%
on 12/26/25
9.3490 -94.35%
on 01/03/25
-5.7332 (-91.57%)
since 12/26/24

Most Recent Stories

More News
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call...

PRPH : 0.5278 (-14.18%)
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on December 1

UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by...

PRPH : 0.5278 (-14.18%)
ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed...

PRPH : 0.5278 (-14.18%)
ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced...

PRPH : 0.5278 (-14.18%)
ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals

UNIONDALE, NY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) reminds shareholders of record as of October 20, 2025, of the Company's upcoming Special Meeting of Stockholders, which...

PRPH : 0.5278 (-14.18%)
ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology

Peer-Reviewed Study Conducted in Collaboration with Mayo Clinic Demonstrates 100% Sensitivity and Strong Predictive Power for Esophageal Cancer Progression Early Access Programs and Physician Onboarding...

PRPH : 0.5278 (-14.18%)
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts

UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced...

PRPH : 0.5278 (-14.18%)
ProPhase Labs to Present at the 2025 ThinkEquity Conference

UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced...

PRPH : 0.5278 (-14.18%)
ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology

Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating Potential UNIONDALE, NY, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:...

PRPH : 0.5278 (-14.18%)
ProPhase Labs Signs Sales Agreement with WestPark Capital

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Prophase...

PRPH : 0.5278 (-14.18%)

Business Summary

ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals...

See More

Key Turning Points

3rd Resistance Point 0.6983
2nd Resistance Point 0.6641
1st Resistance Point 0.6396
Last Price 0.5278
1st Support Level 0.5809
2nd Support Level 0.5467
3rd Support Level 0.5222

See More

52-Week High 9.3490
Fibonacci 61.8% 5.9715
Fibonacci 50% 4.9282
Fibonacci 38.2% 3.8850
Last Price 0.5278
52-Week Low 0.5075

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar